Denmark vs. US Vaccine Schedules: A Policy Analysis

Source: Why Denmark's vaccine schedule is not right for the U.S. | STAT

Executive Summary (The Elevator Pitch)

Reports suggest the Department of Health and Human Services may adopt Denmark's minimalist childhood vaccine schedule, but this Stanford infectious disease physician argues that would be a mistake for the United States. Denmark doesn't routinely vaccinate children against RSV, rotavirus, chickenpox, hepatitis A and B, flu, or meningococcal disease—not because the science is different, but because Denmark has universal healthcare that can absorb the hospitalizations these diseases cause, while the US system cannot. The author presents data showing these vaccines have prevented tens of thousands of US hospitalizations annually, and argues that even with better healthcare, preventing disease is preferable to treating it.

Author & Institutional Information

Author: Jake Scott, MD

• Infectious diseases physician and clinical associate professor at Stanford University School of Medicine
• Co-author of recent NEJM systematic review on RSV prevention

Conflicts of Interest: Not explicitly disclosed in this opinion piece

Publication: STAT First Opinion (opinion/editorial section, not peer-reviewed research)

The Data & Arguments

Denmark omits these routine vaccines:

• RSV prevention (nirsevimab/maternal vaccine)
• Rotavirus
• Varicella (chickenpox)
• Hepatitis B at birth (uses selective screening instead)
• Hepatitis A
• Annual influenza
• Meningococcal disease

US outcomes cited for each:

• RSV: Nirsevimab reduces infant hospitalizations by ~80%; maternal vaccine by 55-68%. Madrid saw ~90% fewer pediatric ICU admissions, Chile saw 75% reduction in hospitalizations.
• Rotavirus: Before 2006 vaccine: 2.7 million cases, 55,000-70,000 hospitalizations, 20-60 deaths annually. Post-vaccine: 85-95% reduction in hospitalizations.
• Varicella: Before 1995 vaccine: 4 million cases, 11,000-13,500 hospitalizations, 100-150 deaths annually. UK recently decided to add varicella vaccine in 2026 based on US data.
• Hepatitis B: 12-18% of US pregnancies go unscreened. When infants are infected perinatally, 90% develop chronic infection, 25% die from disease.
• Hepatitis A: 31,000 cases in 1995, dropped to 1,398 by 2011 (95% reduction) after universal childhood vaccination.
• Influenza: 2024-25 season had 288 child deaths (deadliest in 15 years), 89% of those with known status were not fully vaccinated.
• Meningococcal: 10-15% fatality rate, can kill within 24 hours. Many developed countries (UK, Australia, Canada, Germany, etc.) have routine programs.

Strengths

• Uses real-world implementation data from multiple countries (Spain, Chile, UK) alongside clinical trial data, strengthening the argument beyond theoretical benefits.
• Provides historical context showing what happened before vaccines (actual hospitalization and death numbers) and after implementation, making the stakes concrete and understandable.
• Acknowledges Denmark's reasoning rather than dismissing it—recognizes Denmark made a values-based decision appropriate for their healthcare system, making this a policy debate rather than a science debate.
• Cites peer-reviewed evidence including the author's own NEJM systematic review, lending credibility to the RSV claims.
• Compares globally, not just US vs. Denmark to show Denmark is an outlier even among Nordic countries with similar healthcare systems, undermining the "universal healthcare solves this" argument.

Weaknesses

• No disclosed conflicts of interest in an opinion piece about vaccines—readers can't assess if the author has consulting relationships, research funding, or other ties to vaccine manufacturers.
• Limited engagement with Denmark's perspective—doesn't explain what evidence or reasoning led Denmark to their decisions, making it harder to evaluate the competing arguments fairly.
• Minimal discussion of vaccine risks or downsides—focuses almost entirely on benefits without addressing safety signals, adverse events, cost-effectiveness analyses, or parental concerns that inform policy decisions.
• Cherry-picks the 2024-25 flu season as "deadliest in 15 years" without discussing whether this was an outlier or trend, or what Denmark's flu outcomes look like comparatively.
• Oversimplifies the healthcare access argument—assumes universal coverage would eliminate disparities, but doesn't address whether Denmark's "acceptable" hospitalization rate would actually be unacceptable in the US with better access.
• Doesn't address vaccine hesitancy implications—a maximalist schedule in a country with declining vaccine confidence could potentially reduce uptake of critical vaccines, but this isn't discussed.
• No cost-benefit analysis—doesn't discuss whether the resources spent on some of these vaccines (especially annual flu vaccination for all children) might be better deployed elsewhere in a resource-constrained system.

The Bottom Line

This is a well-argued opinion piece making a legitimate policy point: different healthcare systems justify different prevention strategies. However, it's advocacy rather than analysis—presenting the strongest case for comprehensive vaccination without deeply engaging with the counterarguments or trade-offs that presumably led Denmark and other countries to different conclusions.